Elapegademase Explained

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.^[1]

It is a recombinant enzyme^[2] that is administered weekly by intramuscular injection.^[3]

Elapegademase may interact with PEGylated drugs.^[3]

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.^{[4] [5] [6]} Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.^[7]

External links

• Web site: Elapegademase . U.S. National Library of Medicine. Drug Information Portal.

Notes and References

1. Book: Skidmore-Roth L . Mosby's 2023 Nursing Drug Reference . 2022 . Elsevier Health Sciences . 978-0-323-93330-8 . 429 . Elapegademase . https://books.google.com/books?id=S2ZsEAAAQBAJ&dq=Elapegademase&pg=PA429.
2. Web site: Elapegademase: Drug Information . subscription . www.uptodate.com . 28 March 2019.
3. Web site: LexiComp: Elapegademase-lvlr . subscription . LexiComp . 28 March 2019.
4. Web site: Drug Approval Package: Revcovi . U.S. Food and Drug Administration (FDA) . 7 November 2018 . 26 December 2019.
5. Web site: Elapegademase-lvlr Orphan Drug Designation and Approval . U.S. Food and Drug Administration (FDA) . 24 December 1999 . 26 December 2019.
6. Web site: Drug Trial Snapshot: Revcovi . U.S. Food and Drug Administration (FDA) . 5 October 2018 . 26 December 2019.
7. Web site: Elapegademase - Leadiant Biosciences . AdisInsight . subscription. Springer Nature Switzerland AG . 28 March 2019.